05/18/2017
https://congress.gov...
"The Medicaid program is often called the innovation incubator."
"We have seen how our healthcare system has benefitted from the competition that comes with a robust market."
"I worry that this inappropriately treats biosimilars like generic drugs and will disincentivize manufacturers from entering the biosimilars marketplace."
"I do worry that it is important in the case of biosimilars or generics that that continue to be a way of reducing drug pricing."